- Home
- SEVN vs ZNTL Comparison
SEVN vs ZNTL Comparison
Compare SEVN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ZNTL
- Stock Information
- Founded
- SEVN 1986
- ZNTL 2014
- Country
- SEVN United States
- ZNTL United States
- Employees
- SEVN N/A
- ZNTL N/A
- Industry
- SEVN Real Estate Investment Trusts
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- ZNTL Health Care
- Exchange
- SEVN Nasdaq
- ZNTL Nasdaq
- Market Cap
- SEVN 135.0M
- ZNTL 118.3M
- IPO Year
- SEVN N/A
- ZNTL 2020
- Fundamental
- Price
- SEVN $8.69
- ZNTL $1.34
- Analyst Decision
- SEVN Strong Buy
- ZNTL Buy
- Analyst Count
- SEVN 2
- ZNTL 7
- Target Price
- SEVN $13.50
- ZNTL $6.17
- AVG Volume (30 Days)
- SEVN 196.0K
- ZNTL 702.2K
- Earning Date
- SEVN 10-27-2025
- ZNTL 11-10-2025
- Dividend Yield
- SEVN 12.70%
- ZNTL N/A
- EPS Growth
- SEVN N/A
- ZNTL N/A
- EPS
- SEVN 1.04
- ZNTL N/A
- Revenue
- SEVN $29,408,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SEVN N/A
- ZNTL N/A
- Revenue Next Year
- SEVN N/A
- ZNTL N/A
- P/E Ratio
- SEVN $8.50
- ZNTL N/A
- Revenue Growth
- SEVN N/A
- ZNTL N/A
- 52 Week Low
- SEVN $8.62
- ZNTL $1.01
- 52 Week High
- SEVN $13.97
- ZNTL $4.16
- Technical
- Relative Strength Index (RSI)
- SEVN 29.68
- ZNTL 40.42
- Support Level
- SEVN $8.62
- ZNTL $1.25
- Resistance Level
- SEVN $10.90
- ZNTL $1.41
- Average True Range (ATR)
- SEVN 0.28
- ZNTL 0.10
- MACD
- SEVN -0.06
- ZNTL -0.01
- Stochastic Oscillator
- SEVN 12.92
- ZNTL 22.04
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.